Kaliumchlorid/Glucose B. Braun (Potassium Chloride, Glucose)

Potassium chloride dissociates to release potassium ions, directly raising extracellular potassium and correcting deficiency. Glucose supplies immediate energy and stimulates insulin release, which helps drive potassium into cells, improving cellular uptake and supporting metabolic processes during intravenous treatment.

The specific dose and infusion rate are determined by the prescribing clinician based on the patient’s serum potassium, renal function, and overall clinical condition. Healthcare professionals calculate the appropriate amount to safely correct potassium deficits and meet glucose needs.

Safety data for use in pregnancy or lactation are limited. The product should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by the treating physician after evaluating the clinical situation.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Kaliumchlorid/Glucose combines potassium chloride with glucose, offering both electrolyte correction and an energy source in a single infusion. Compared with plain potassium chloride solutions, it may reduce the need for separate dextrose administration and can help mitigate hypoglycemia, but clinicians must monitor both potassium and glucose levels closely.

The product should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. Before use, inspect for particulate matter or discoloration and allow the solution to reach room temperature if required for administration.

Kaliumchlorid/Glucose is administered intravenously by slow infusion, typically through a peripheral or central line. The infusion rate is set by the prescriber based on the patient’s potassium level, renal function, and clinical status, and the solution should be diluted as recommended in the product labeling.

The most serious risks include severe hyperkalemia, which can cause life‑threatening cardiac arrhythmias, and severe hypoglycemia, especially when insulin is co‑administered. Anaphylactic reactions and metabolic acidosis are also rare but critical adverse events that require immediate medical attention.

Patients with known hypersensitivity to potassium chloride, glucose, or any excipients in the formulation should avoid this product. It is also contraindicated in individuals with severe hyperkalemia, uncontrolled diabetes with high risk of hypoglycemia, or those with severe renal impairment where potassium accumulation cannot be safely managed.